Search results
Results From The WOW.Com Content Network
At AstraZeneca our industry-leading pipeline includes investigational therapies in various stages of clinical development - from approved medicines to earlier-stage molecules in clinical trials.
Our broad pipeline of next-generation medicines, together with our focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers.
Explore the AstraZeneca Oncology Pipeline by Tumour Type, Cell Pathway and Scientific Pillars.
AstraZeneca's David Fredrickson spoke to Fierce Biotech as the FDA accepted an application for the TROP2-directed ADC datopotamab deruxtecan.
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.
After three years in a phase 1/2 solid tumour trial, data have finally emerged on AstraZeneca’s B7-H4 ADC puxitatug samrotecan and they look – at best – in line with results from similarly acting agents.
AstraZeneca, home of cancer blockbusters like Tagrisso and Daiichi Sankyo-partnered Enhertu, wants to elevate its cancer pipeline and is sharing a peek at data from three bispecific antibody...
Rajan Sharma’s rating is based on the strength and potential of AstraZeneca’s oncology pipeline, which was highlighted during the recent ESMO conference. His assessment suggests that the...
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Sachin Jain has given his Buy rating due to a combination of factors including AstraZeneca’s solid sales performance and robust oncology franchise, which align closely with consensus estimates.